Cypress Capital Group Amgen Inc Transaction History

Cypress Capital Group

  • $879 Million
  • Q3 2024

A detailed history of Cypress Capital Group transactions in Amgen Inc stock. As of the latest transaction made, Cypress Capital Group holds 13,519 shares of AMGN stock, worth $3.92 Million. This represents 0.5% of its overall portfolio holdings.

Number of Shares
13,519
Previous 13,383 1.02%
Holding current value
$3.92 Million
Previous $4.18 Million 4.16%
% of portfolio
0.5%
Previous 0.51%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024
BUY
$309.38 - $337.38 $42,075 - $45,883
136 Added 1.02%
13,519 $4.36 Million
Q2 2024

Jul 25, 2024
SELL
$262.75 - $319.31 $432,749 - $525,903
-1,647 Reduced 10.96%
13,383 $4.18 Million
Q1 2024

May 08, 2024
BUY
$268.87 - $324.56 $136,585 - $164,876
508 Added 3.5%
15,030 $4.27 Million
Q4 2023

Jan 24, 2024
BUY
$255.7 - $288.46 $45,003 - $50,768
176 Added 1.23%
14,522 $4.18 Million
Q3 2023

Nov 02, 2023
BUY
$218.65 - $271.46 $86,366 - $107,226
395 Added 2.83%
14,346 $3.86 Million
Q2 2023

Jul 26, 2023
BUY
$214.27 - $253.37 $572,100 - $676,497
2,670 Added 23.67%
13,951 $3.1 Million
Q1 2023

May 04, 2023
SELL
$225.79 - $275.2 $478,900 - $583,699
-2,121 Reduced 15.83%
11,281 $2.73 Million
Q4 2022

Feb 14, 2023
BUY
$229.03 - $291.01 $34,125 - $43,360
149 Added 1.12%
13,402 $3.52 Million
Q3 2022

Nov 04, 2022
BUY
$224.46 - $253.15 $80,805 - $91,134
360 Added 2.79%
13,253 $2.99 Million
Q2 2022

Jul 26, 2022
SELL
$230.71 - $256.74 $541,014 - $602,055
-2,345 Reduced 15.39%
12,893 $3.14 Million
Q1 2022

May 16, 2022
BUY
$219.27 - $242.57 $427,795 - $473,254
1,951 Added 14.68%
15,238 $3.69 Million
Q4 2021

Feb 15, 2022
SELL
$198.88 - $227.6 $87,109 - $99,688
-438 Reduced 3.19%
13,287 $2.99 Million
Q3 2021

Oct 12, 2021
SELL
$212.27 - $248.7 $205,265 - $240,492
-967 Reduced 6.58%
13,725 $2.92 Million
Q2 2021

Jul 13, 2021
SELL
$233.58 - $259.14 $91,096 - $101,064
-390 Reduced 2.59%
14,692 $3.58 Million
Q1 2021

Apr 14, 2021
SELL
$221.91 - $258.6 $233,671 - $272,305
-1,053 Reduced 6.53%
15,082 $3.75 Million
Q4 2020

Jan 12, 2021
BUY
$216.38 - $257.67 $54,744 - $65,190
253 Added 1.59%
16,135 $3.71 Million
Q3 2020

Oct 08, 2020
BUY
$234.65 - $260.95 $66,405 - $73,848
283 Added 1.81%
15,882 $4.04 Million
Q2 2020

Jul 10, 2020
BUY
$197.81 - $242.74 $809,240 - $993,049
4,091 Added 35.55%
15,599 $3.68 Million
Q1 2020

Apr 08, 2020
SELL
$182.24 - $241.7 $50,662 - $67,192
-278 Reduced 2.36%
11,508 $2.33 Million
Q4 2019

Jan 10, 2020
BUY
$189.21 - $243.2 $73,791 - $94,848
390 Added 3.42%
11,786 $2.84 Million
Q3 2019

Oct 10, 2019
SELL
$174.11 - $208.62 $13,406 - $16,063
-77 Reduced 0.67%
11,396 $2.21 Million
Q2 2019

Aug 15, 2019
SELL
$166.7 - $195.41 $85,017 - $99,659
-510 Reduced 4.26%
11,473 $2.11 Million
Q1 2019

May 14, 2019
SELL
$180.87 - $203.88 $1.27 Million - $1.43 Million
-7,038 Reduced 37.0%
11,983 $2.28 Million
Q4 2018

Feb 19, 2019
BUY
$178.4 - $208.25 $165,020 - $192,631
925 Added 5.11%
19,021 $3.7 Million
Q3 2018

Nov 15, 2018
BUY
$185.29 - $208.89 $131,185 - $147,894
708 Added 4.07%
18,096 $3.75 Million
Q2 2018

Aug 15, 2018
BUY
$166.05 - $186.51 $409,479 - $459,933
2,466 Added 16.53%
17,388 $3.21 Million
Q1 2018

May 21, 2018
BUY
$169.43 - $198.0 $186,542 - $217,998
1,101 Added 7.97%
14,922 $2.54 Million
Q4 2017

Feb 14, 2018
SELL
$168.79 - $188.59 $130,305 - $145,591
-772 Reduced 5.29%
13,821 $2.4 Million
Q3 2017

Nov 16, 2017
BUY
$167.29 - $191.0 $186,361 - $212,774
1,114 Added 8.26%
14,593 $2.72 Million
Q2 2017

Aug 15, 2017
BUY
N/A
13,479
13,479 $2.32 Million

Others Institutions Holding AMGN

# of Institutions
3,122
Shares Held
410M
Call Options Held
7.56M
Put Options Held
7.2M
View Full List

About AMGEN INC

AMGN Quotes by TradingView
  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $155B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Cypress Capital Group Portfolio

Follow Cypress Capital Group and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cypress Capital Group, based on Form 13F filings with the SEC.

News

Stay updated on Cypress Capital Group with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email